Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | September 11, 2025 | September 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date September 11, 2025 · Filed September 15, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 38,766 |
Reported balance
After 2025-09-11 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-09-11 · Grant · Acquired 23,100 · Balance 38,766 F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F4: This amended Form 4 corrects the number of stock options reported in the original Form 4 filed on September 15, 2025. The original filing incorrectly stated that 23,000 restricted stock units were granted. The correct number of restricted stock units granted was 23,100. Securities beneficially owned changed from 38,666 to 38,766. F2: Includes shares of common stock underlying unvested restricted stock units. F3: The number of reported securities has been adjusted to reflect prior reverse stock splits. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2: Includes shares of common stock underlying unvested restricted stock units.
F3: The number of reported securities has been adjusted to reflect prior reverse stock splits.
F4: This amended Form 4 corrects the number of stock options reported in the original Form 4 filed on September 15, 2025. The original filing incorrectly stated that 23,000 restricted stock units were granted. The correct number of restricted stock units granted was 23,100. Securities beneficially owned changed from 38,666 to 38,766.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2025 Filed Sep 15, 2025 20:02 UTC Amendment | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 23,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006986 · ownership.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,766 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F4 · shares: This amended Form 4 corrects the number of stock options reported in the original Form 4 filed on September 15, 2025. The original filing incorrectly stated that 23,000 restricted stock units were granted. The correct number of restricted stock units granted was 23,100. Securities beneficially owned changed from 38,666 to 38,766. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. F4 · balance_after: This amended Form 4 corrects the number of stock options reported in the original Form 4 filed on September 15, 2025. The original filing incorrectly stated that 23,000 restricted stock units were granted. The correct number of restricted stock units granted was 23,100. Securities beneficially owned changed from 38,666 to 38,766. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 12:29 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006957 · ownership.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,666 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:59 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,500 | $2.42 | $6,049.75 |
DisclosureSEC source: 0001062993-25-011423 · form4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,666 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| May 20, 2025 Filed May 21, 2025 20:13 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,500 | $1.82 | $4,550.00 |
DisclosureSEC source: 0001062993-25-009985 · form4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at $1.82. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the transactions. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:11 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-006334 · ownership.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one year on the first anniversary. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 21:00 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,000 | $3.10 | $6,200.00 |
DisclosureSEC source: 0001209191-23-037408 · doc4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:20 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011932 · doc4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 5,000 | $0.41 | $2,041.00 |
DisclosureSEC source: 0001209191-22-059702 · doc4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.4075 to $0.4089. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 21:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,000 | $0.41 | $819.80 |
DisclosureSEC source: 0001209191-22-058862 · doc4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 01:06 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010391 · doc4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 02:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 682 | $3.15 | $2,148.30 |
DisclosureSEC source: 0001209191-21-017572 · doc4.xml · nonDerivative · entry 2 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 02:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017572 · doc4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,318 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Effective as of 12:01 a.m. Eastern Time on January 15, 2020, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-55. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 00:24 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 127,500 | $0.10 | $12,750.00 |
DisclosureSEC source: 0001209191-19-057494 · doc4.xml · nonDerivative · entry 1 Ferrara Robert L · CIK 0001792987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.